- Home
- NXG vs APLT Comparison
NXG vs APLT Comparison
Compare NXG & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXG
- APLT
- Stock Information
- Founded
- NXG 2012
- APLT 2016
- Country
- NXG United States
- APLT United States
- Employees
- NXG N/A
- APLT N/A
- Industry
- NXG
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- NXG
- APLT Health Care
- Exchange
- NXG Nasdaq
- APLT Nasdaq
- Market Cap
- NXG 211.3M
- APLT 178.6M
- IPO Year
- NXG N/A
- APLT 2019
- Fundamental
- Price
- NXG N/A
- APLT $1.25
- Analyst Decision
- NXG
- APLT Buy
- Analyst Count
- NXG 0
- APLT 5
- Target Price
- NXG N/A
- APLT $4.13
- AVG Volume (30 Days)
- NXG 24.4K
- APLT 12.4M
- Earning Date
- NXG 01-01-0001
- APLT 11-06-2025
- Dividend Yield
- NXG 14.78%
- APLT N/A
- EPS Growth
- NXG N/A
- APLT N/A
- EPS
- NXG N/A
- APLT N/A
- Revenue
- NXG N/A
- APLT $121,000.00
- Revenue This Year
- NXG N/A
- APLT N/A
- Revenue Next Year
- NXG N/A
- APLT $5,935.35
- P/E Ratio
- NXG N/A
- APLT N/A
- Revenue Growth
- NXG N/A
- APLT N/A
- 52 Week Low
- NXG $30.32
- APLT $0.30
- 52 Week High
- NXG $42.29
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- NXG 58.83
- APLT 68.25
- Support Level
- NXG $49.13
- APLT $0.90
- Resistance Level
- NXG $50.50
- APLT $1.16
- Average True Range (ATR)
- NXG 0.71
- APLT 0.21
- MACD
- NXG 0.02
- APLT 0.03
- Stochastic Oscillator
- NXG 69.40
- APLT 88.15
About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest
Cushing NextGen Infrastructure Income Fund is a closed-end investment management company. Its investment objective is to seek a high total return with a focus on current income. The Fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies, and technology & communication infrastructure companies.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.